Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


 

E-learning: Update on Renal cell carcinoma with prof. Camillo Porta

04/03/2019

During a special Speaker Tour meeting prof. Camillo Porta visited the NKI-AVL to discuss challenges and best practices within the changing treatment landscape in (m)RCC.  ‘With the development of new therapeutic systemic options for the treatment of mRCC, including immunotherapy, novel TKIs and combination treatment, we find ourselves standing at the verge of a new era of therapeutic possibilities.  Our challenge is to find the best possible treatment algorithm for each (m)RCC patient.’ Topics that are discussed in this e-learning are: When are we ready for adjuvant therapy? What is the role of cytoreductive nephrectomy in mRCC? How to choose from the available options for first, second, and third line treatment? What may be the impact of immunotherapy and novel TKIs on the treatment algorithm? Chair and co-discussant: prof. J. Haanen, medical oncologist, NKI-AVL

 

Quarterly Focus on GU | Bladder Cancer

21/11/2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Michiel van der Heijden, MD, PhD - medical oncologist, Netherlands Cancer Institute, Amsterdam Prof. Fred Witjes, MD -  urologist, Radboudumc, Nijmegen Sjoukje Oosting, MD, PhD - medical oncologist, UMCG, Groningen Program: Speaker: Prof. Dipen Parekh, MD – urologist at University of Miami Health System in Miami, USA Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial Lancet 391, 2018 Speaker: Michiel van der Heijden, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam, The Netherlands Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Lancet 391, 2017

 

ESMO 2018 in depth: Resistance mechanisms to osimertinib in patients with NSCLC and a EGFR T790M mutation

21/10/2018

Vassiliki Papadimitrakopoulou, MD, oncologist at the MD Anderson Cancer Centre in Texas, provides information on EGFR mutations associated with resistance to osimertinib in patients with NSCLC and a T790M mutation. These results are from an analysis of the AURA3 study.

  • 00:04:23
 

EMUC 2018: Frail patients and the CARMENA trial

13/12/2018

Dr. Umberto Capitanio, urologist at the IRCCS Ospedale San Raffaele in Italy and chief editor of the kidney cancer section of the UROONCO educational platform, talks about the EMUC 2018 discussion about frail patients. Furthermore he mentions the discussion about the Carmena trial in which nephrectomy plus adjuvant sunitinib is compared to sunitinib alone in patients with metastatic renal cell cancer.

  • 00:04:22
 

Multidisciplinary Immuno-Oncology Symposium: Bart Neyns

15/10/2018

Melanoma: when to stop immuno therapy? Blockade of the programmed cell death protein 1 (PD-1, CD279) cell surface receptor relicenses anti-tumor T-cell activity in a tumor micro-environment with expression of the programmed death-ligand 1(PD-L1; CD274) on tumor- and/or other tumor infiltrating cells. The PD-1 blocking monoclonal antibodies (mAb) pembrolizumab and nivolumab demonstrated an overall survival (OS) benefit when compared to ipilimumab or dacarbazine as first line therapy in patients with advanced melanoma.1-3Objective responses were observed in 27-40% of advanced melanoma patients and found to be durable in the majority of patients.1,4 One- and 2-year survival rates were in the order of 57% to 70%. Follow-up of patients treated on a phase I clinical trial with nivolumab revealed that anti-tumor responses were ongoing after the cessation of PD-1 therapy; 12 (71%) of 17 patients who stopped therapy for reasons other than PD maintained their responses for at least 16 weeks off-treatment.5 Similarly, in the phase I KEYNOTE-001 trial, the 24-month disease-free survival (DFS) from time of complete tumor response (CR) was 89.9% in the subgroup of 67 patients who stopped pembrolizumab treatment after obtaining a CR (and who proceeded to observation without additional anticancer therapy).6 In the phase III KEYNOTE-006 trial, pembrolizumab was administered for a maximum duration of 24 months in patients with stable disease (SD), partial response (PR) and CR as best response. In the subgroup of 103 patients who stopped treatment after the 24 months interval, 14 patients (15%) developed PD after a median follow up of 20.3 mo (range, 0.03-24.8). Patients were at higher risk for progression during their second year off therapy and a higer proportion of patients who stopped PEMBRO with a best response of PR or SD were at higher risk as compared to patients who had a CR at the time of stopping PEMBRO.7 The estimated risk for progression or appeared to differ by best response to pembrolizumab. A complete metabolic tumor response on FDG-PET/CT at one year following initiation of anti-PD1 may have utility in addition to CT based response assessment in predicting long-term progression-free survival. 8 We previously reported on the outcome of advanced melanoma patients treated with PD-1 therapy outside of an interventional clinical trial.9 This academic real-world cohort study was extended investigating the outcome of 185 advanced melanoma patients who electively discontinued anti-PD-1 therapy with pembrolizumab (n = 167) or nivolumab (n = 18) in the absence of PD or treatment-limiting toxicity at 14 medical centers across Europe and Australia demonstrating that advanced melanoma patients who electively discontinued anti-PD-1 therapy in the absence of TLT or PD had a low risk for early disease progression, seemingly regardless of the duration of treatment (manuscript currently under review).

  • 00:38:48
 

Quarterly Focus on Genitourinary Cancer: highlights in prostate cancer (part 2)

17/12/2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Niven Mehra, MD, PhD – medical oncologist, Radboudumc, Nijmegen Andre Bergman, MD, PhD – medical oncologist, Netherlands Cancer Institute, Amsterdam Prof. Theo de Reijke, MD - urologist, Amsterdam UMC, Amsterdam Program: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE) N Engl J M, July 27, 2017 Speaker: Karim Fizazi, MD, PhD - medical oncologist, Gustave Roussy Institute, Villejuif, France Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial The Lancet, Oct 21, 2018 Speaker: Prof. Nicholas James, PhD - medical oncologist, University of Birmingham, UK

 

ASCO 2018 Results of the TAILORx trial

27/06/2018

Joseph Sparano, oncologist at Montefiore Medical Center, explains the results of the TAILORx trial, which he presented during the plenary session at ASCO 2018. This trial attempted to incorporate a gene expression test into clinic decision making for hormone receptor positive breast cancer.

  • 00:06:50
 

ASCO GU 2018: Renal Cell Carcinoma News Program

22/03/2018

This year the ASCO Genitourinary Cancers Symposium took place in San Francisco from February 8th - 10th. In this Renal Cell Carcinoma News Program, we focus on the highlights for RCC at this congress. Moderator Catherine Hood and a panel of international experts discuss the following topics: Adjuvant systemic therapy Cabozantinib in the first line treatment of metastatic RCC The NIVOREN trial that investigates nivolumab in a ‘real world setting’ Combination treatments with VEGF and PD1/PD-L1 inhibition Advances in treatment for papillary RCC Speakers: Prof. Joaquim Bellmunt, MD, medical oncologist, Dana-Farber/Brigham and Women's Cancer Center, Boston Daniel George, MD, medical oncologist, Duke Cancer Center, Durham Jeanny Aragon-Ching, MD, medical oncologist, Inova Fairfax hospital, Fairfax Sumanta Pal, MD, medical oncologist, City of Hope Comprehensive Cancer Center, Duarte Moderator: Catherine Hood

  • 00:39:40

Click here to select your areas of interest

Areas of interest

Select to filter on program types

Congress news 10/10/2019

ESMO 2019 Osimertinib as first-line treatment for NSCLC: final OS analysis

The FLAURA-studie compares the effectivity of the EGFR tyrosine kinase inhibitor (EGFR-TKI) osimertinib to the EGFR-TKI's gefitinib of erlotinib in NSCLC. In 2018, benefit in progression-free survival was reported for osimertinib. At this ESMO congress, dr. Suresh Ramalingam (Winship Cancer Institute of Emory University), presented the results on overall survival.

Congress news 10/10/2019

ESMO 2019 Veliparib with carboplatin and paclitaxel in HER2-negative breast cancer

At this ESMO congress, medical oncologist Véronique Diéras presented a late breaking abstract on the BROCADE-3 trial. In this trial the effectivity and tolerability of veliparib with chemotherapy was investigated in patients with BRCA-positive HER2-negatieve breast cancer. In this interview, Dr. Diéras summarizes the main findings.

Congress news 08/10/2019

ESMO 2019 Analysis of tumor hyperprogression with nivolumab in RCTs

Pulmonologist prof. Martin Reck from the LungenClinic Großhansdorf in Germany presented results on a relatively new phenomenon: tumor hyperprogression after treatment with immunotherapy. In the CheckMate 451 cohort, the occurence of this phenomenon with nivolumab-treated es-SCLC patients was evaluated.

Congress news 01/10/2019

ESMO 2019 Highlights Breastcancer

Prof. Guy Jerusalem, MD, PhD, medical oncologist at the CHU de Liège in Belgium, shares his view on the most important ESMO news for breastcancer.   

E-learnings 04/03/2019

E-learning: Update on Renal cell carcinoma with prof. Camillo Porta

During a special Speaker Tour meeting prof. Camillo Porta visited the NKI-AVL to discuss challenges and best practices within the changing treatment landscape in (m)RCC.  ‘With the development of new therapeutic systemic options for the treatment of mRCC, including immunotherapy, novel TKIs and combination treatment, we find ourselves standing at the verge of a new era of therapeutic possibilities.  Our challenge is to find the best possible treatment algorithm for each (m)RCC patient.’ Topics that are discussed in this e-learning are: When are we ready for adjuvant therapy? What is the role of cytoreductive nephrectomy in mRCC? How to choose from the available options for first, second, and third line treatment? What may be the impact of immunotherapy and novel TKIs on the treatment algorithm? Chair and co-discussant: prof. J. Haanen, medical oncologist, NKI-AVL

Meet the author 17/12/2018

Quarterly Focus on Genitourinary Cancer: highlights in prostate cancer (part 2)

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Niven Mehra, MD, PhD – medical oncologist, Radboudumc, Nijmegen Andre Bergman, MD, PhD – medical oncologist, Netherlands Cancer Institute, Amsterdam Prof. Theo de Reijke, MD - urologist, Amsterdam UMC, Amsterdam Program: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE) N Engl J M, July 27, 2017 Speaker: Karim Fizazi, MD, PhD - medical oncologist, Gustave Roussy Institute, Villejuif, France Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial The Lancet, Oct 21, 2018 Speaker: Prof. Nicholas James, PhD - medical oncologist, University of Birmingham, UK

Congress news 13/12/2018

EMUC 2018: Radiomics

Prof. Philippe Lambin, radiation oncologist at the University of Maastricht (the Netherlands), and dr. Jochen Walz, urologist at the Institut Paoli-Calmettes (France), are enthousiastic about radiomics. This tool is developed to standardize radiologic examinations as a means to become independent of personal performance.